Which agent is described as an emerging nerve growth factor-3 inhibitor for osteoarthritis?

Which agent is described as an emerging nerve growth factor-3 inhibitor for osteoarthritis?

• A. Levicept
• B. MTX
• C. Prednisone
• D. NSAIDs

Answer: (B)

Emerging nerve growth factor inhibitors work by directly blocking NGF signaling to reduce pain transmission in osteoarthritis. NGF normally binds to receptors on pain-sensing nerves, lowering their sensitivity and amplifying pain. By neutralizing NGF with monoclonal antibodies, these therapies can lessen OA pain more specifically than standard analgesics. Examples in development include anti-NGF antibodies like tanezumab, fasinumab, and fulranumab, which are designed to dampen pain signaling rather than simply masking symptoms. Among the options listed, none are anti-NGF agents. Methotrexate is a disease-modifying drug used mainly for inflammatory arthritis, not an NGF inhibitor. NSAIDs reduce pain and inflammation by inhibiting COX enzymes but do not target NGF. Prednisone is a corticosteroid with broad anti-inflammatory effects, not NGF-directed. Levicept targets VEGF rather than NGF. Therefore, the described emergent NGF-inhibitor therapy would be an anti-NGF antibody such as tanezumab, not any of these agents.

Emerging nerve growth factor inhibitors work by directly blocking NGF signaling to reduce pain transmission in osteoarthritis. NGF normally binds to receptors on pain-sensing nerves, lowering their sensitivity and amplifying pain. By neutralizing NGF with monoclonal antibodies, these therapies can lessen OA pain more specifically than standard analgesics. Examples in development include anti-NGF antibodies like tanezumab, fasinumab, and fulranumab, which are designed to dampen pain signaling rather than simply masking symptoms.

Among the options listed, none are anti-NGF agents. Methotrexate is a disease-modifying drug used mainly for inflammatory arthritis, not an NGF inhibitor. NSAIDs reduce pain and inflammation by inhibiting COX enzymes but do not target NGF. Prednisone is a corticosteroid with broad anti-inflammatory effects, not NGF-directed. Levicept targets VEGF rather than NGF. Therefore, the described emergent NGF-inhibitor therapy would be an anti-NGF antibody such as tanezumab, not any of these agents.